Skip to main content
Schott Pharma logo

Schott Pharma — Investor Relations & Filings

Ticker · 1SXP ISIN · DE000A3ENQ51 LEI · 529900TU48UE99NHEY88 F Manufacturing
Open in API
Filings indexed 137 across all filing types
Latest filing 2026-05-13 Earnings Release
Country DE Germany
Listing F 1SXP

About Schott Pharma

https://www.schott-pharma.com/en

Schott Pharma is a developer and manufacturer of drug containment solutions and delivery systems for injectable drugs. Serving the pharmaceutical and biotech industries, its portfolio includes prefillable syringes, cartridges, vials, and ampoules. The company provides scientifically proven products designed for the safe storage and administration of medications. Beyond individual components, Schott Pharma offers complete, compatible systems and a range of services, including analytical, development, fill-and-finish, and regulatory support. This integrated approach supports clients from clinical trials through to commercialization, ensuring compatibility across the entire pharma value chain.

Recent filings

Filing Released Lang Actions
SCHOTT Pharma mit robustem erstem Halbjahr und starkem Cashflow
Earnings Release Classification · 90% confidence The document is a corporate news release summarizing SCHOTT Pharma’s first‐half (H1 2026) financial results. It provides key metrics (revenues, EBITDA, cash flow), segment breakdowns, management commentary, outlook and webcast details. It is not the full half‐year report with complete financial statements, but rather an initial announcement of period results. This aligns with an Earnings Release. H1 2026
2026-05-13 German
Half-yearly financial report 2025/2026
Interim / Quarterly Report Classification · 95% confidence The document is titled “Half-Year Financial Report H1 2026” and covers the period October 1, 2025 to March 31, 2026. It includes an Interim Group Management Report, condensed interim consolidated financial statements (income statement, balance sheet, cash flows, notes), a review report and supplementary information. This is a comprehensive financial report for a half-year period (shorter than a full fiscal year) and contains actual financial data. Therefore, it fits the definition of an Interim/Quarterly Report (IR). H1 2026
2026-05-13 English
Presentation H1 2026
Investor Presentation Classification · 92% confidence The document is a detailed presentation titled “H1 2026 Results Presentation” by the CEO and CFO of SCHOTT Pharma, containing slide-based financial updates (revenue, EBITDA, segment performance), strategy highlights, guidance, cash flow analysis, and upcoming events. This fits the definition of an Investor Presentation, rather than an interim report (IR) itself or a mere announcement. Therefore, it should be classified as an Investor Presentation (IP).
2026-05-13 English
SCHOTT Pharma AG & Co. KGaA: Dr. Torsten Derr, buy
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction in the company's shares by a person discharging managerial responsibilities (Dr. Torsten Derr, a member of the administrative or supervisory body). It explicitly follows the standard format for 'Directors' Dealings' or 'Managers' Transactions' under market abuse regulations, detailing the nature of the transaction (acquisition), the financial instrument (shares), the price, volume, and the date of the transaction. This aligns perfectly with the definition for 'Director's Dealing' (DIRS).
2026-02-12 English
SCHOTT Pharma with positive start to financial year 2026; outlook confirmed
Earnings Release Classification · 100% confidence The document is a corporate news release announcing the Q1 2026 financial results for SCHOTT Pharma. It provides key highlights such as revenue growth, EBITDA margins, and segment performance, and confirms the company's outlook. While it contains financial data, it is structured as an initial announcement (Earnings Release) rather than a full quarterly report or a report publication announcement. It follows the standard format for an earnings release disseminated via a news service (EQS). Q1 2026
2026-02-11 English
Q1 statement / Q1 financial report 2025/2026
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Statement Q1 2026' and covers the period from October 1, 2025 to December 31, 2025, which is a quarter of the fiscal year. It contains detailed financial data including revenue, EBITDA, EBIT, cash flows, segment performance, and other substantive financial information. The length is about 15,000 characters, indicating a comprehensive report rather than a brief announcement. The content includes consolidated statements of income, financial position, cash flows, and detailed business performance analysis. This matches the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year containing actual financial statements and substantive analysis. Therefore, the correct classification is IR with high confidence.
2026-02-11 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.